Zydus Lifesciences Q2 Net Profit up by 53% Y-o-Y

livemint.com:

Key Financial Highlights

Q2 FY24 Highlights “Our Q2 FY24 result represents stable growth in our key businesses, as well as strong profitability. We are on track to meet our growth objectives for the year. Going ahead, differentiated launches in the US, in addition to a rebound in India business growth which was constrained by delayed seasonality, will be critical drivers.

We anticipate sustained momentum in profitability and aim for EBITDA margins of more than 24% in the current fiscal year." Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited

Q2 FY24 Business-wise Sales Performance(Consolidated) Q2 FY24 Business Updates
India Geography Formulations business Consumer Wellness business US formulations business Emerging Markets (EM) and Europe formulations business API business Alliances & Others Updates on Innovation Pipeline

NCE: ZYIL1 NCE: PCSK9 inhibitor Biotech R&D Specialty Initiatives About Zydus Lifesciences Limited
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The group employs 25,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.